An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ropeginterferon alfa-2b (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Feb 2016 Results will be presented at the 25th Conference of the Asian Pacific Association for the Study of the Liver 2016, according to a PharmaEssentia Corporation media release.
- 22 Feb 2016 Status changed from recruiting to completed, based on the information presented in a PharmaEssentia Corporation media release.
- 02 May 2012 Status changed from planning to recruiting, according to ClinicalTrials.gov.